Global Myocardial Infarction Treatment Market 2022-2028

Description

List of Tables

Global Myocardial Infarction TreatmentMarket Size, Share & Trends Analysis Report byType (ST segment elevation myocardial infarction (STEMI) Heart Attacks, Non-ST segment elevation myocardial infarction (NSTEMI) Heart Attacks, and Silent Heart Attacks), by Device (Left Ventricular Assist Device, Pacemaker, Implantable Cardioverter Defibrillator, and Others), by Diagnosis (Electrocardiography (ECG), Chest X-Ray, Computed Tomography (CT Scan), Echocardiography, and Others), by Treatment (Medication andSurgery), and by End-User(Hospital & Clinics, Ambulatory Surgical Centers, and Research Institutes) Forecast (2022-2028)

The global myocardial infarction treatment market is anticipated to grow at a considerable CAGR of 5.1% during the forecast period.Rising incidence rate of CVDs (cardiovascular diseases) and intake of high-level sugary food contributes to the growth of the myocardial infarction market during the forecast period. According to WHO,CVDs are the leading cause of death globally, taking an estimated 17.9 million lives each year. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.

The high cost of myocardial infarction treatment and delay in certification for heart treatment are some factors restraining the growth of the market. However, the supportive laws and schemes for the reduction and prevention of heart diseases and the rising adoption of minimally invasive treatment are anticipated to create the future opportunity for the growth of the myocardial infarction market.

The global myocardial infarction treatment market is segmented based on the type, device, diagnosis, treatment, and end-user. Based on the type, the market is sub-segmented into ST segment elevation myocardial infarction (STEMI) heart attacks, non-ST segment elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on, the device, the market is sub-segmented into the left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others. Based on, the diagnosis, the market is sub-segmented into the electrocardiography (ECG), chest x-ray, computed tomography (CT scan), echocardiography, and others. Based on, the treatment, the market is sub-segmented into the medication and surgery. Further, on the basis of end-user, the market is sub-segmented into hospital & clinics, ambulatory surgical centers, and research institutes. On the basis of

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.Europe is the second largest market for myocardial infarction treatment across the globe, owing to favorable reimbursement policies and supportive laws and schemes for healthcare technology are some of the major factors fuelling the growth of the market in the region.Growing healthcare spending and improving healthcare system is another factor contributing to the growth of myocardial infarction treatment market during the forecast period in European region. According to the European Union Healthcare expenditure was highest among the EU Member States in Luxembourg (EUR 5 502 per inhabitant), Denmark (EUR 5 355 per inhabitant) and Sweden (EUR 5 042 per inhabitant) in 2019.

The major companies serving the global myocardial infarction treatment market include Bayer AG, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market.

Research Methodology

The market study of the global myocardial infarction treatment marketis incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Myocardial Infarction Treatment Market Research and Analysis by Type.

2. Global Myocardial Infarction Treatment Market Research and Analysis by Devices.

3. Global Myocardial Infarction Treatment Market Research and Analysis by Diagnosis.

4. Global Myocardial Infarction Treatment Market Research and Analysis by Treatment.

5. Global Myocardial Infarction Treatment Market Research and Analysis by End-Users.

The Report Covers

Comprehensive research methodology of the global myocardial infarction treatment market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global myocardial infarction treatment market.
Insights about market determinants that are stimulating the global myocardial infarction treatment market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2019522

Category- Medical Devices

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Myocardial Infarction Treatment Market
Recovery Scenario of Global Myocardial Infarction Treatment Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. BY Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. Bayer AG
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. GlaxoSmithKline PLC
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Novartis AG
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Pfizer Inc.
- 3.5.1. Overview
- 3.5.2. Financial Analysis
- 3.5.3. SWOT Analysis
- 3.5.4. Recent Developments
3.6. Teva Pharmaceutical Industries Ltd.
- 3.6.1. Overview
- 3.6.2. Financial Analysis
- 3.6.3. SWOT Analysis
- 3.6.4. Recent Developments
3.7. Key Strategy Analysis
3.8. Impact of Covid-19 on Key Players

4. Market Segmentation

4.1. Global Myocardial Infarction Treatment Market by Type
- 4.1.1. ST segment elevation myocardial infarction (STEMI) Heart Attacks
- 4.1.2. Non-ST segment elevation myocardial infarction (NSTEMI) Heart Attacks
- 4.1.3. Silent Heart Attacks
4.2. Global Myocardial Infarction Treatment Market by Device
- 4.2.1. Left Ventricular Assist Device
- 4.2.2. Pacemaker
- 4.2.3. Implantable Cardioverter Defibrillator
- 4.2.4. Others (Aspiration-Based Catheters)
4.3. Global Myocardial Infarction Treatment Market by Diagnosis
- 4.3.1. Electrocardiography (ECG)
- 4.3.2. Chest X-Ray
- 4.3.3. Computed Tomography (CT Scan)
- 4.3.4. Echocardiography
- 4.3.5. Others (Blood Test)
4.4. Global Myocardial Infarction Treatment Market by Treatment
- 4.4.1. Medication
  - 4.4.1.1. Analgesics
  - 4.4.1.2. Thrombolytic
  - 4.4.1.3. Antiplatelet Agents
  - 4.4.1.4. Glycoprotein IIb/IIIa Inhibitors
  - 4.4.1.5. Others (Adrenergic Blockers)
- 4.4.2. Surgery
  - 4.4.2.1. Angioplasty
  - 4.4.2.2. Bypass Surgery
  - 4.4.2.3. Heart Transplant
4.5. Global Myocardial Infarction Treatment Market by End-Users
- 4.5.1. Hospital & Clinics
- 4.5.2. Ambulatory Surgical Centers
- 4.5.3. Research Institutes

5. Regional Analysis

5.1. North America
- 5.1.1. US
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Abliva AB
6.2. advanceCOR GmbH
6.3. AstraZeneca
6.4. Athersys, Inc.
6.5. BioVascular Inc.
6.6. Boehringer Ingelheim International GmbH.
6.7. Bristol Myers Squibb (BMS)
6.8. Caladrius Biosciences, Inc.
6.9. Capricor Therapeutics
6.10. CSL Behring LLC
6.11. Egetis Therapeutics AB
6.12. GNT Pharma Co., Ltd
6.13. Johnson & Johnson Services, Inc.
6.14. Merck KGaA
6.15. Mesoblast Ltd.
6.16. Osiris Therapeutics, Inc.
6.17. Sandoz International GmbH
6.18. Sanofi
6.19. Viatris Inc.